ID 405232207 · FY 2019–2024 · 6 years
კომპანიის ძირითად საქმიანობას წარმოადგენს მედიკამენტებით და სამედიცინო სახარჯი მარაგებით საბითუმო ვაჭრობა.
Bars are revenue on the left axis; lines are EBITDA and net margin on the right.
| Ratio | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Margins | ||||||
| Gross Margin | 54.1% | 49.1% | 44.8% | 34.1% | 33.3% | 31.2% |
| EBITDA Margin | 42.7% | 34.3% | 39.4% | 24.0% | 16.3% | 12.7% |
| EBITDAR | 1,057 | 911 | 2,249 | 1,706 | 928 | 754 |
| EBITDAR Margin | 43.0% | 34.6% | 39.6% | 25.9% | 19.7% | 16.0% |
| EBIT Margin | 42.6% | 34.1% | 39.4% | 24.0% | 15.9% | 12.4% |
| Net Profit Margin | 40.6% | 31.0% | 37.1% | 24.4% | 12.2% | 10.2% |
| Operating Expense % of Sales | 11.3% | 14.8% | 5.4% | 10.1% | 17.0% | 18.5% |
| Returns | ||||||
| Return on Assets (ROA) | 56.6% | 37.4% | 58.9% | 20.6% | 11.7% | 11.3% |
| Return on Equity (ROE) | 59.6% | 40.1% | 64.5% | 41.4% | 16.4% | 14.3% |
| ROIC [EBIT / Invested Capital] | 62.8% | 42.4% | 75.9% | 40.0% | 23.0% | 17.6% |
| Leverage & liquidity | ||||||
| Debt-to-Assets | 4.9% | 6.8% | 0.0% | 2.8% | 0.0% | 0.0% |
| Debt-to-Equity | 0.05x | 0.07x | 0.00x | 0.06x | 0.00x | 0.00x |
| Debt-to-EBITDA | 0.08x | 0.16x | 0.00x | 0.14x | 0.00x | 0.00x |
| Equity-to-Assets | 94.9% | 93.2% | 91.3% | 49.8% | 71.0% | 79.2% |
| Net Debt | -4 | 83 | -322 | 66 | -242 | -45 |
| Cash & Equivalents | 90 | 65 | 322 | 154 | 242 | 45 |
| Total Debt | 86 | 148 | N/A | 219 | N/A | N/A |
| Efficiency & working capital | ||||||
| Inventory Turnover | 2.44x | 2.29x | N/A | N/A | N/A | N/A |
| Days Inventory Outstanding (DIO) | 149.8 | 159.3 | N/A | N/A | N/A | N/A |
| Receivables Turnover | 2.07x | 1.74x | 2.11x | 1.87x | 1.52x | 1.60x |
| Days Sales Outstanding (DSO) | 176.6 | 210.0 | 173.4 | 194.9 | 239.8 | 228.6 |
| Payables Turnover | 307.74x | N/A | 10.04x | 1.18x | 2.42x | 3.93x |
| Days Payable Outstanding (DPO) | 1.2 | N/A | 36.4 | 308.5 | 150.8 | 92.8 |
| Cash Conversion Cycle | 325.2 days | 369.2 days | 137.0 days | -113.6 days | 89.0 days | 135.8 days |
| Asset Turnover | 1.39x | 1.21x | 1.59x | 0.85x | 0.95x | 1.11x |
| Cash flow & dividends | ||||||
| Operating Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow (OCF − Capex proxy) | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Conversion (OCF / EBITDA) | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends Declared | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividend Payout Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Money rows — EBITDAR, net debt, cash, total debt, operating and free cash flow, dividends declared — are in ₾ '000. Margins, returns and payout are percentages; turnover and leverage are multiples; DIO/DSO/DPO are days. Hover a metric name for its definition.
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Companies sharing this sub-sector, ranked by how close their latest revenue is to this one — not a curated comp set.